Nasonex (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This binding alters gene transcription, suppressing the release of inflammatory cytokines and mediators while enhancing anti‑inflammatory proteins. The result is reduced swelling, mucus production, and vascular permeability, which alleviates nasal symptoms.

The exact dosing regimen for Nasonex is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and clinical response. In many adult cases, the typical regimen involves one spray into each nostril once daily, but the prescriber may adjust frequency or amount as needed.

Safety data for mometasone furoate in pregnancy and lactation are limited. The medication should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider to weigh benefits against possible exposure to the infant.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Nasonex contains mometasone furoate, which has a high receptor affinity and low systemic bioavailability, similar to other intranasal steroids such as fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in relieving allergic rhinitis symptoms, while the once‑daily dosing schedule of Nasonex may offer convenience for some patients.

Store Nasonex at room temperature, below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the spray tip remains clean. Do not freeze the product, and keep it out of reach of children.

Before use, gently shake the bottle and prime the spray by pressing the actuator several times until a fine mist appears. Tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril with a finger, and press the actuator while breathing in gently. Repeat in the other nostril if prescribed.

Serious but rare risks include adrenal suppression, especially with prolonged high‑dose use, increased intraocular pressure that may lead to glaucoma, cataract formation, and severe allergic reactions such as anaphylaxis. Patients should report persistent nosebleeds, visual changes, or signs of systemic corticosteroid effects to their healthcare provider promptly.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal or sinus infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid therapy is contraindicated without medical supervision.